Campylobacter concisus

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Campylobacter concisus is a Gram-negative, non-spore-forming, microaerophilic, motile, rod-shaped - curved bacterium. It has been detected in at least 12 gut microbiome compilation studies or metastudies. The DNA G+C content is 37–41%. Campylobacter concisus is probably a common, although minor, coloniser of the gut. (Kaakoush2012; Tanner1981; Vandamme1991; VanDamme2005Bergey; Liu2018a)



  • This organism has been recovered from human faeces, and oral cavity. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread. It is an opportunistic pathogen. Is a known gut commensal. Robust growth can have negative consequences for gut health.
    • GENERAL CHARACTERISTICS (Kaakoush2012); (Tanner1981); (Vandamme1991); (VanDamme2005Bergey);
    Character Response
  • 🧂
  • Salt tolerance:
  • strain-variable at 2.0(d)%;
  • 💧
  • Bile tolerance:
  • Strain-variable at 2%
  • 🌡
  • Temperature tolerance:
  • doesn't grow at 25℃; strain-variable at 42(d);
  • ⥅
  • Substrates assimilated or utilised:
  • formate; fumarate;
  • ±
  • Strain-dependent substrate utilisation:
  • glycine;
  • Active enzymes:
  • esterase C4; esterase lipase C8; Leu arylamidase;
  • ±
  • Strain-dependent active enzymes:
  • oxidase;
    • SPECIAL FEATURES (Kaakoush2012); (Tanner1981); (VanDamme2005Bergey);
    Character Response
  • ✓
  • Metabolites produced:
  • acetate; succinate; H₂S; CO₂; H₂;
  • ✗
  • Metabolites not produced:
  • indole;
  • ✗
  • VP test:
  • not active
  • ✓
  • Nitrate:
  • reduced
  • ±
  • Nitrite:
  • reduced by few strains
    • RESPONSE TO ANTIBIOTICS (Goldstein2003); (Kaakoush2012); (Tanner1981); (VanDamme2005Bergey);
    Class Active Resistant
  • Penicillins:
  • ampicillin; carbenicillin; imipenem;
  • piperacillin;
  • Cephalosporins:
  • cefotaxime; cephalothin;
  • cefalexin; cefazolin; cefoperazone; cefoxitin; ceftazidime; moxalactam;
  • Macrolides:
  • azithromycin; erythromycin;
  • Tetracyclines:
  • minocycline; tetracycline;
  • Quinolines:
  • nalidixic-acid;
  • Aminoglycosides:
  • streptomycin;
  • amikacin; neomycin;
  • Polypep/ketides:
  • bacitracin;
  • rifampicin;
  • Heterocycles:
  • chloramphenicol; metronidazole;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin; colistin; polymyxin B;
  • NOTES

    Media containing 1% glycine supports growth of some strains.

  • Bacterium Selenite reduction H2S/TSI Nitrate reduction Oxidase Catalase Indoxyl acetate hydrolysis
    Campylobacter coli + d + + + +
    Campylobacter upsaliensis + neg + + neg +
    Campylobacter rectus + neg + + d +
    Campylobacter showae + d + d + neg
    Campylobacter concisus d neg d d neg neg
    Campylobacter curvus neg d + + neg d
    Campylobacter gracilis neg neg d neg d d
    Campylobacter hominis neg neg neg + neg neg

  • Vandamme, P., Falsen, E., Pot, B., Hoste, B., Kersters, K., & De Ley, J. (1989). Identification of EF group 22 campylobacters from gastroenteritis cases as Campylobacter concisus. Journal of Clinical Microbiology, 27(8), 1775–1781.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Proteobacteria Class:  Epsilonproteobacteria Order:  Campylobacterales Family:  Campylobacteraceae Genus:  Campylobacter Gram stain:  neg O2 Relation.:  microaerophilic Spore:  No spore Motility:  Swimming Morphology:  Rod - curved
    Health:   Negative
    Source:  human faeces, and oral cavity
    DNA G+C(%):  37–41
    Lower T(℃):  25(neg)
    High T(℃):  42(d)
    NaCl 0.5-2%:  2.0(d)
    Bile reaction(%):  2(d)
    		Aesculin:  neg Urea:  neg Gelatin:  neg Starch:  neg Casein:  neg DNA:  neg Tyrosine:  neg Hippurate:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Fructose:  neg Glucose:  neg Maltose:  neg Sucrose:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Gly:  d(neg) Hippurate:  neg Formate:  + Fumarate:  +
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  d Catalase:  neg Urease:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  neg α-Mannosidase:  neg ArgDC:  neg γ-Glu transf.:  neg LysDC:  neg OrnDC:  neg LeuAA:  + PyrrolidAA:  neg AlkalineP:  vr AcidP:  neg Esterase(C4):  + EstLip(C8):  + Lecithinase:  neg Lipase:  neg Lipase(C14):  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Acetate:  + Succinate:  + H2S:  + CO2:  + H2:  + Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  Var(MIC50): 0.125, MIC90: >8, RNG: (0.06->8)
    ampicillin:  SensRNG: (0.38-2)
    carbenicil:  S(32)
    penicillin:  Var(MIC50): 0.5-8), MIC90: Var(0.5-8
    penicillin_G:  Var(MIC50): 0.25, MIC90: >32, RNG: (≤0.03->32)
    piperacillin:  R(128)
    imipenem:  S(1)
    cefalexin:  R(MIC50): >32, MIC90: >32, RNG: (2->32)
    cefazolin:  R(128)
    cefoperazone:  R(128)
    cefotaxime:  S(4)
    cefoxitin:  R(128)
    ceftazidime:  R(64)
    cephalothin:  S(32)
    moxalactam:  R(128)
    amikacin:  R(64)
    gentamicin:  Var(MIC50): 2->32), MIC90: Var(2->32
    kanamycin:  Var(MIC50): 1-10), MIC90: Var(1-10
    neomycin:  R(16-32)
    streptomycin:  SensRNG: (1-12)
    azithromycin:  S(MIC50): 0.125, MIC90: 0.5, RNG: (0.125-0.5)
    erythromycin:  S(MIC50): 0.25, MIC90: 2, RNG: (0.25-2)
    ciprofloxacin:  Var(MIC50): ≤0.5, MIC90: >8, RNG: (≤0.5->8)
    levofloxacin:  Var(MIC50): 0.25, MIC90: >8, RNG: (≤0.06->8)
    nalidixic-acid:  Var(MIC50): 32-128), MIC90: Var(32-128, vr)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    minocycline:  S(2)
    tetracycline:  S(MIC50): 0.25, MIC90: 1, RNG: (0.125-2)
    vancomycin:  R(128)
    bacitracin:  S(128)
    rifampicin:  R(16-64)
    chloramphenicol:  S(4)
    metronidazole:  S(MIC50): 1, MIC90: 4, RNG: (0.25-4)
    clindamycin:  S(MIC50): 0.25, MIC90: 2, RNG: (0.125-4)
    colistin:  SensRNG: (0.5-1)
    polymyxin_B:  SensRNG: (≤0.25-1)

    References

    SPECIFIC REFERENCES FOR CAMPYLOBACTER CONCISUS
  • Goldstein2003 - In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates.
  • Kaakoush2012 - Campylobacter concisus - A New Player in Intestinal Disease.
  • Tanner1981 - Wolinella gen. nov., Wolinella succinogenes (Vibrio succinogenes Wolin et al.) comb. nov., and Description of Bacteroides gracilis sp. nov., Wolinella recta sp. nov., Campylobacter concisus sp. nov., and Eikenella corrodens from Humans with Periodontal Disease.
  • Vandamme1991 - Revision of Campylobacter, Helicobacter, and Wolinella Taxonomy: Emendation of Generic Descriptions and Proposal of Arcobacter gen. nov.
  • VanDamme2005Bergey - Bergey's manual of systematic bacteriology. Vol. 2, The Alpha-, Beta-, Delta-, and Epsilonproteobacteria Part C. Family Campylobacteraceae, Genus I. Campylobacter
  • Liu2018a - The Clinical Importance of Campylobacter concisus and Other Human Hosted Campylobacter Species.
  • Chen2020a - Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease
  • Finegold2002 - Gastrointestinal microflora studies in late-onset autism
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR CAMPYLOBACTER CONCISUS
  • Bik2006 - Molecular analysis of the bacterial microbiota in the human stomach.
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • De2020 - Metagenomic analysis of gut microbiome and resistome of diarrheal fecal samples from Kolkata, India, reveals the core and variable microbiota including signatures of microbial dark matter.
  • Forster2019 - A human gut bacterial genome and culture collection for improved metagenomic analyses.
  • Hu2019 - The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • New2022 - Collective effects of human genomic variation on microbiome function.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Walker2011 - High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease.
  • Yang2020 - Species-Level Analysis of Human Gut Microbiota With Metataxonomics.
  • Yang2020a - Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • GENERAL REFERENCES FOR CAMPYLOBACTER CONCISUS
  • CCUG - Culture Collection University of Gothenburg - Entire Collection
  • VanDamme2005Bergey - Bergey's manual of systematic bacteriology. Vol. 2, The Alpha-, Beta-, Delta-, and Epsilonproteobacteria Part C. Family Campylobacteraceae, Genus I. Campylobacter
  • VanDamme2005aBergey - Bergey's manual of systematic bacteriology. Vol. 2, The Alpha-, Beta-, Delta-, and Epsilonproteobacteria Part C. Family Campylobacteraceae, Genus II. Arcobacter
    • Added: April 08, 2021